Recent clinical trials found PD-L1 expression on immune cells to be prognostic in patients with head and neck cancer (85), non–small cell lung cancer (86), triple-negative breast cancer (87), and renal cell carcinoma (88) treated with ICB. Here, CD274 is linked to lung cancer.